As of December 31, 2018, the Company had approximately $63.9 million net-operating-loss carry forwards, consisting of approximately $12.0 million of Maltese net-operating-loss carry forwards and approximately 51.9 million Israeli net-operating-loss carry forward. Additionally, the Company had approximately $1.2 million of capital loss carry forward from the sale of marketable debt securities. The Maltese and the Israeli loss carry forwards have no expiration date.

BC Residents and Investor Disclaimer : Effective September 15 2008 – all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Given the number of parameters that improved in mice in the Blasco study, (BMD, insulin, memory, …), it looks feasible to me (although certainly expensive) to establish the same improvements in humans in a relatively short time (3-5 years). That could give them a lot more credibility.

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Our research and development expenses amounted to approximately $8.3 million during the year ended December 31, 2018, representing a decrease of approximately $1.4 million, or approximately 14%, compared to approximately $9.7 million for the year ended December 31, 2017. The decrease primarily resulted from a decrease in research and development subcontractor expenses in connection with the completion of the ARREST Study of approximately $2.5 million; partially offset by an increase of approximately $0.5 million in salaries and benefits paid to new employees hired since the comparable prior year period. We expect that research and development expenses will significantly increase through 2019 and beyond.

This association was attenuated but remained statistically significant after further multivariable adjustment for lifestyle, cardiovascular factors, metabolic factors, red blood cell indices, iron storage indices, and liver function indices (HR, 2.90; 95% CI, 1.25 to 6.76).

NK cells were loaded with 5 μM Fluo-4 AM (Invitrogen) in HBSS at 37°C for 40 min and changes in [Ca2+]i were determined at 488 nm excitation/530 nm emission wavelengths using a confocal microscope (Nikon). For calculation of [Ca2+]i, the method of Tsien et al.38 was used with the following equation: [Ca2+]i = Kd(F − Fmin)/(Fmax − F), where Kd is 335 nM for Fluo-4, and F is the observed fluorescence. Each tracing was calibrated for maximal intensity (Fmax) by addition of ionomycin (8 μM) and for minimal intensity (Fmin) by addition of EGTA 50 mM after each measurement.

Acrux Limited   ( ASX:ACR.AX ) develops and commercializes a range of patient-preferred and patented pharmaceutical products using its technology to administer proven medicines through the skin. The company’s products include Axiron to treat testosterone deficiency in men; Evamist for menopause symptoms; and Recuvyra pain relief for dogs. Its product under registration comprises Estradiol MDTS for menopause symptoms. The company is also developing Luramist for female HSDD; Nestorone MDTS for contraception; Nicotine MDTS for smoking cessation; and NSAIDs for pain and inflammation. It operates in Australia, accessing international pharmaceutical markets through commercial partners.

As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity. Therefore, obtaining and enforcing pharmaceutical patents is costly, time-consuming and inherently uncertain. In particular, the United States has recently enacted, and is currently implementing, wide-ranging patent reform legislation. The United States Supreme Court has ruled on several patent cases in recent years, and could do so again in the future, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by applicable courts and legislatures in the countries in which we may pursue patent protection, including those of the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents and the interpretations of such laws could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.

Aspirin: It seems that a low dose of Aspirin in the range of 50 – 81 mg or even as low as 30 mg has the same anti-blodd-clotting effects as a normal to high dose of 300 – 1200 mg. 1) https://books.google.de/books?id=GnIQGmiSylkC&pg=PA1108&lpg=PA1108&dq=aspirin+75mg&source=bl&ots=iXpVbhuZQ7&sig=m1sJvOT_tDJzHXcony2F9MATen0&hl=de&sa=X&ved=0ahUKEwi01cuq_bDQAhVKDsAKHRMOAYY4ChDoAQhzMAM#v=onepage&q=aspirin%2075mg&f=false 2) https://www.ncbi.nlm.nih.gov/pubmed/4082090 3) https://www.ncbi.nlm.nih.gov/pubmed/10870801

Mannikko, R., Pandey, S., Larsson, H. P. & Elinder, F. Hysteresis in the voltage dependence of HCN channels: conversion between two modes affects pacemaker properties. J Gen Physiol 125, 305–26 (2005).